In addition,
Abivax: after positive clinical results new: Moreover. For example,
Abivax: after positive clinical results:
(BFM Stock Exchange) – The title of the Biotechnologies company flies by almost 400% in reaction to the announcement of positive clinical results for its potential treatment for hemorrhagic rectocolitis. Meanwhile, chronic inflammation of the intestinal mucosa.
Spectacular increase for Abivax. Furthermore. Nevertheless, which is to be put to the assets of the publication of positive clinical results for a chronic inflammatory disease of the intestinal mucosa, hemorrhagic rectocolitis. Nevertheless,
The action of the company of biotechnologies specializing in chronic inflammatory diseases is flying from almost 400% to 44.50 euros, this Wednesday, July 23, propelled to historical summits since its IPO in 2015. For example, Biotech thus sees its recovery jump to more than 2.8 billion euros.
Positive results – Abivax: after positive clinical results new
In a statement published this abivax: after positive clinical results new Wednesday. Meanwhile. Moreover, Abivax announced positive results for two phase III trials abivax: after positive clinical results (that is to say the last stage of clinical trials before a potential placing on the market, editor’s note) by evaluating the Obefazimod molecule in the treatment of rectocolite hemorragic moderately at severely active. Moreover, Rectocolite hemorrhagic is a very disabling disease that reaches the rectum and often the colonist. In addition, It affects a million people in the United States and as much in Europe. For example,
The two studies. Therefore. ABTECT-1 and ABTECT-2, carried out simultaneously and included a total of 1,275 patients in more than 600 clinical trial centers distributed in 36 countries. Patients recruited in this trial were both naive of any treatment as patients in failure. loss of response to previous advanced therapies.
According to the results announced by Abivax. a dose of 50 mg of abivax: after positive clinical results new Obefazimod administered once a day for eight weeks led to a “very significant. rate of remission” clinical abivax: after positive clinical results of 16.4 % for the two studies grouped, corrected from the placebo effect at week 8 in the Abtect-1 and Abtect-2 trials.
The company also adds that the main secondary evaluation criteria have also been reached. and that the product has been generally well tolerated in the two doses groups.
“The solidity of these results reinforces our conviction in the potential of Obefazimod. our modulator of the expression of MIR-124 first in its class. to become a new transformative therapeutic option for patients suffering from rectocolite hemorrhagic moderately active,” commented Marc de Garidel, director general of Abivax.
“The molecule that we develop to stimulate another which regulates the immune system. especially when you have too much inflammation in the body. In the case of hemorrhagic rectocolitis, abivax: after positive clinical results new as in Crohn’s disease, the intestine ignites and causes very strong inconvenience. And in the most extreme cases. we can even remove abivax: after positive clinical results your intestine,” explained the leader of Abivax in 2023 BFM Business.
Abivax: after positive clinical results new
Abivax: after positive clinical results
A “Maintenance” study
A “maintenance” study is underway. to verify the efficiency. tolerance of treatment over a period of 44 weeks and whose results are expected in the second quarter of 2026.
“This study will include 678 patients among the 1. 275 who followed the induction trial: cohort of responders with a clinical response,” adds Invest Securities.
Subject to positive results of the maintenance trial. Abivax plans to submit a market for marketing authorization (New Drug Application) to the Food. Drug Administration, the American Health Authority, in the second half of 2026.
The company had raised a little more abivax: after positive clinical results new $ 235 million at an entry into the Nasdaq stock exchange in October 2023. to finance the development of its potential treatment for hemorrhagic rectocolitis.
“The good news is that abivax: after positive clinical results Abivax is one of the rare companies to. have been able to raise. money on the Nasdaq. We made the largest fundraising by going up to the French biotechs”. was then congratulated at the time Marc de Garidel.
The company specifies that its cash position on June 30 was 61 million euros (non-AUS figures). and that the publication of its financial results for the first half will be postponed to September 8 against August 11 initially.
Sabrina Sadgui – ©2025 BFM Bourse
Do you follow this action?
Receive all info on ABIVAX in real time: abivax: after positive clinical results new
Further reading: This crazy bet of Elon Musk is likely to fail miserably – Alan, the “unicorn” brooded by Macronie to energize the French mutualist model – Current drilling work on René-Lévesque for the tramway – Trump cuts | The American Environment Agency removes a quarter of its workforce – Trump 2.0: return their size to emerging markets.
Further reading: Faced with Trump, the European Union anticipates the worst scenarios – Cyberattaque: “support for hacked SMEs varies from region to region” – Europe ends in dispersed order with trade tensions – 07/21/2025 at 18:13 – “Three pedal strokes for the taxman” – NIQ Global aims for a valuation of $ 7.3 billion during its IPO in the United States, marking the return of the quotes supported by the investment capital.
